Beijing Med-Pharm Corporation Signs Agreement with Shanghai Ethypharm to Market Ondansetron Once Approved in China.PLYMOUTH MEETING, Pa. -- Beijing Med-Pharm Corporation (Nasdaq:BJGP BJGP British Journal of General Practice ) today announced that it has signed an exclusive license agreement with Shanghai Ethypharm Pharmaceutical Co., Ltd., a subsidiary of the French drug delivery company Ethypharm, under which Beijing Med-Pharm will market and distribute ondansetron Flashtab[R] (4 and 8 mg) in the People's Republic People's Republic n. A political organization founded and controlled by a national Communist party. of China. Under the terms of the agreement, Shanghai Ethypharm will pursue registration of ondansetron Flashtab[R] in China, a process expected to be completed in 2009. Beijing Med-Pharm will then be responsible for sales, marketing, distribution and supply. "Ondansetron is a significant global product that complements our plans in oncology and the portfolio of supportive therapies Supportive therapy Any form of treatment intended to relieve symptoms or help the patient live with them rather than attempt changes in character structure. we are building for that market, including Galake, the analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs we recently licensed from Lotus," said David Gao, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Beijing Med-Pharm. "We are very pleased to be entering our first collaboration with one of Europe's leading drug delivery companies." "Ethypharm has made a significant corporate commitment to entering Asian markets and we believe there is a substantial opportunity in China for our Flashtab[R] ondansetron product," said Philippe Malecki, General Manager of Shanghai Ethypharm. "Offering comprehensive sales and marketing support as well as a proprietary distribution system reaching major Chinese markets, we believe Beijing Med-Pharm represents a unique resource for expediting the successful launch of this product and generating rapid sales growth." Ondansetron is the generic form of Zofran[R], the global leader in the 5-HT3 antagonist antagonist /an·tag·o·nist/ (an-tag´o-nist) 1. a substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response, blocking binding of substances that could class of antiemetics. Ondansetron has been used in millions of patients around the world to reduce nausea and vomiting Nausea and Vomiting Definition Nausea is the sensation of being about to vomit. Vomiting, or emesis, is the expelling of undigested food through the mouth. induced by cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic chemotherapy and radiotherapy and to prevent
post-operative nausea and vomiting. Ethypharm manufactures the product
using its proprietary Flashtab[R] orally disintegrating tablet The Food and Drug Administration's (FDA) definition of an orally disintegrating tablet (ODT) is: "A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue. technology.
About Shanghai Ethypharm Shanghai Ethypharm Pharmaceutical Co., Ltd., is a subsidiary of Ethypharm, one of the world's leading drug delivery systems (DDS (1) (Digital Data Storage) See DAT. (2) (Data Dictionary System) See QuickBuild and OpenDDS. (3) (Dataphone Digital S ) companies that provides a range of effective solutions to optimize the delivery of pharmaceutical products. The use of Ethypharm's DDS technologies delivers important benefits including improving the drug's efficacy, enhancing patient compliance and comfort, extending the life cycles of existing pharmaceutical products, and reducing the total cost of treatment. Ethypharm is an established DDS company with capabilities from research through manufacturing and has successfully launched 50 products in over 70 countries. For further information about Ethypharm, please visit www.ethypharm.com. About Beijing Med-Pharm Corporation Beijing Med-Pharm is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical products in China and pursuing partnerships with other companies seeking to enter the Chinese pharmaceuticals market. Beijing Med-Pharm is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis; clinical trial management; product registration; market research; pharmaceutical distribution to hospitals through a unique proprietary network; and pharmaceutical marketing to physicians, hospitals and other healthcare providers. For further information about Beijing Med-Pharm, please visit www.beijingmedpharm.com. Forward Looking Statements In addition to historical facts or statements of current condition, this press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. within the meaning of the "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, including statements regarding the successful completion of registration of ondansetron in China, the market opportunity for ondansetron in China, the successful product launch of ondansetron in China and the ability to generate rapid sales growth of ondansetron in China. Forward-looking statements provide Beijing Med-Pharm's current expectations or forecasts of future events. Actual results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, and the ability of Shanghai Ethypharm to successfully register ondansetron in China. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Beijing Med-Pharm undertakes no obligation to update publicly any forward-looking statement. Flashtab[R] is a registered trademark of Ethypharm Zofran[R] is a registered trademark of GlaxoSmithKline |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion